Alimera Sciences, Inc. (NASDAQ:ALIM) Logo

Alimera Sciences Inc (ALIM) investors sentiment increased to 2.25 in 2018 Q3. It’s up 1.32, from 0.93 in 2018Q2. The ratio is better, as 18 active investment managers opened new and increased stock positions, while 8 sold and decreased equity positions in Alimera Sciences Inc. The active investment managers in our database now own: 29.16 million shares, down from 29.19 million shares in 2018Q2. Also, the number of active investment managers holding Alimera Sciences Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 6 Increased: 8 New Position: 10.

Analysts expect Ophthotech Corporation (NASDAQ:OPHT) to report $-0.37 EPS on February, 26.They anticipate $0.11 EPS change or 42.31% from last quarter’s $-0.26 EPS. After having $-0.41 EPS previously, Ophthotech Corporation’s analysts see -9.76% EPS growth. The stock increased 2.19% or $0.03 during the last trading session, reaching $1.4. About 138,078 shares traded. Ophthotech Corporation (NASDAQ:OPHT) has declined 46.42% since February 14, 2018 and is downtrending. It has underperformed by 46.42% the S&P500. Some Historical OPHT News: 10/05/2018 – Municipal Employees Retire Sys Of Michigan Buys Into Ophthotech; 01/05/2018 – Ophthotech Initial Top-line Data for Study Expected by the End of 2018; 01/05/2018 – Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura(R) in Combination With Anti-VEGF Therapy in Wet Age-Related Macular Degeneration; 09/05/2018 – OPHTHOTECH 1Q LOSS/SHR 36C, EST. LOSS/SHR 40C (2 EST.); 09/05/2018 – OPHTHOTECH 1Q COLLABORATION REV $0; 09/05/2018 – Ophthotech 1Q Loss/Shr 36c; 19/04/2018 DJ Ophthotech Corp, Inst Holders, 1Q 2018 (OPHT); 09/05/2018 – Ophthotech 1Q Loss $13.1M

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. The company has market cap of $78.49 million. It focuses on diseases affecting the back of the eye or retina. It has a 7.23 P/E ratio. The firm offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema , which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

More notable recent Alimera Sciences, Inc. (NASDAQ:ALIM) news were published by: Seekingalpha.com which released: “Alimera’s Iluvien OK’d in Lebanon – Seeking Alpha” on February 05, 2019, also Seekingalpha.com with their article: “Alimera Sciences affirms record Q4 and FY2018 revenues – Seeking Alpha” published on January 07, 2019, Benzinga.com published: “B. Riley FBR: 3 Reasons To Buy Alimera Sciences (NASDAQ:ALIM) – Benzinga” on June 29, 2018. More interesting news about Alimera Sciences, Inc. (NASDAQ:ALIM) were released by: Nasdaq.com and their article: “EyePoint (EYPT) Gets FDA Approval for Eye Therapy Yutiq – Nasdaq” published on October 17, 2018 as well as Seekingalpha.com‘s news article titled: “Alimera Sciences, Inc. (ALIM) CEO Dan Myers on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: November 06, 2018.

Analysts await Alimera Sciences, Inc. (NASDAQ:ALIM) to report earnings on February, 27. They expect $-0.06 earnings per share, up 40.00% or $0.04 from last year’s $-0.1 per share. After $-0.05 actual earnings per share reported by Alimera Sciences, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

The stock increased 1.82% or $0.02 during the last trading session, reaching $1.12. About 192,003 shares traded or 113.88% up from the average. Alimera Sciences, Inc. (ALIM) has declined 23.66% since February 14, 2018 and is downtrending. It has underperformed by 23.66% the S&P500. Some Historical ALIM News: 31/05/2018 – Alimera Sciences Announces the Reimbursement of ILUVIEN® in Spain; 24/04/2018 – Alimera Sciences Short-Interest Ratio Rises 82% to 9 Days; 31/05/2018 – Alimera Sciences Announces the Reimbursement of ILUVIEN in Spain; 21/04/2018 DJ Alimera Sciences Inc, Inst Holders, 1Q 2018 (ALIM)

Armistice Capital Llc holds 0.41% of its portfolio in Alimera Sciences, Inc. for 6.94 million shares. Venbio Select Advisor Llc owns 6.24 million shares or 0.28% of their US portfolio. Moreover, Jw Asset Management Llc has 0.22% invested in the company for 413,300 shares. The New York-based Knott David M has invested 0.1% in the stock. Acuta Capital Partners Llc, a California-based fund reported 267,500 shares.

Investors sentiment decreased to 0.79 in 2018 Q3. Its down 0.38, from 1.17 in 2018Q2. It fall, as 9 investors sold Ophthotech Corporation shares while 19 reduced holdings. 10 funds opened positions while 12 raised stakes. 15.12 million shares or 12.14% less from 17.21 million shares in 2018Q2 were reported. Jpmorgan Chase has invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Jacobs Levy Equity Management invested in 238,747 shares or 0.01% of the stock. Moreover, Ajo Lp has 0.01% invested in Ophthotech Corporation (NASDAQ:OPHT) for 1.09M shares. 173,774 were accumulated by Geode Limited Liability Company. Royal Fincl Bank Of Canada has 2,293 shares for 0% of their portfolio. Endurance Wealth Mgmt Incorporated stated it has 0% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT). California Pub Employees Retirement System invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Acadian Asset Management Llc stated it has 0.01% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT). Blackrock Inc has invested 0% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT). Renaissance Technology owns 683,400 shares. Citigroup reported 0% stake. Dimensional Fund Advsr L P invested 0% of its portfolio in Ophthotech Corporation (NASDAQ:OPHT). Massachusetts-based State Street has invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Susquehanna Intl Grp Ltd Liability Partnership has 0% invested in Ophthotech Corporation (NASDAQ:OPHT) for 41,501 shares. Northern reported 0% in Ophthotech Corporation (NASDAQ:OPHT).

More notable recent Ophthotech Corporation (NASDAQ:OPHT) news were published by: Nasdaq.com which released: “Recent Analysis Shows Amerco, McKesson, Ophthotech, IQVIA, Highwoods Properties, and ABM Industries Market Influences — Renewed Outlook, Key Drivers of Growth – Nasdaq” on February 08, 2019, also Seekingalpha.com with their article: “Ophthotech acquires Inception 4 in all-stock deal – Seeking Alpha” published on October 31, 2018, Seekingalpha.com published: “Ophthotech inks gene therapy agreements for RP candidate; shares ahead 13% premarket – Seeking Alpha” on June 07, 2018. More interesting news about Ophthotech Corporation (NASDAQ:OPHT) were released by: Seekingalpha.com and their article: “Ophthotech Corporation (OPHT) CEO Glenn Sblendorio on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” published on October 31, 2018 as well as Seekingalpha.com‘s news article titled: “Ophthotech Corp (OPHT) CEO Glenn Sblendorio on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: August 01, 2018.

Since January 2, 2019, it had 0 insider buys, and 4 insider sales for $10,340 activity. $5,017 worth of Ophthotech Corporation (NASDAQ:OPHT) was sold by GUYER DAVID R on Friday, January 4. $389 worth of stock was sold by Westby Keith on Friday, January 4.

Ophthotech Corporation, a biopharmaceutical company, develops novel therapeutics to treat diseases of the back of the eye. The company has market cap of $57.77 million. The Company’s principal product candidate, Fovista, an anti-platelet derived growth factor, is in Phase III clinical development for use in combination with anti-vascular endothelial growth factor drugs for the treatment of wet age-related macular degeneration . It currently has negative earnings. The firm is also developing Zimura, an inhibitor of complement factor C5, for the treatment of dry AMD and wet AMD.

Alimera Sciences, Inc. (NASDAQ:ALIM) Institutional Positions Chart



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *